Comparative Analysis of Red Blood Cells, White Blood Cells, Platelet Count, and Indices in Type 2 Diabetes Mellitus Patients and Normal Controls: Association and Clinical Implications.
complete blood count
diabetes mellitus
disease complication
mean platelet volume/platelet count
neutrophil/lymphocyte ratio
platelet/lymphocyte ratio
platelet/neutrophil ratio
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
06
2023
accepted:
04
09
2023
medline:
12
10
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
epublish
Résumé
Diabetes mellitus (DM) is a major health burden affecting 537 million adults worldwide, characterized by chronic metabolic disorder and various complications. This case control study aimed to assess the impact of type 2 diabetes mellitus (T2DM), including hyperglycemia levels, on hematological parameters and complete blood count (CBC) derived parameters. A total of 250 known diabetic patients from the Jazan Diabetic Center, Saudi Arabia, between January 2021 and December 2022, along with 175 healthy adult controls were recruited from Jazan Hospital's blood donation center. Demographic characteristics, medical histories, and relevant factors such as gender, age, BMI, treatment, disease duration, and comorbidities were collected with informed consent. The results of the red blood cell (RBC) count, RBC indices, and mean platelet volume showed significant differences between patients and controls, while the white cell (WBC) and platelet count were comparable between the two groups. CBC-derived parameters, especially neutrophil/lymphocyte ratio (NLR), and platelet/neutrophil ratio (PNR) exhibited significant differences. CBC and derived parameters serve as inexpensive tools for T2DM patients monitoring, indicating early blood cell alterations and potential development of anemia. Further studies are needed to explore their role in predicting T2DM pathogenesis and progression, aiming to reduce severe complications, mortality and morbidity.
Sections du résumé
Background
UNASSIGNED
Diabetes mellitus (DM) is a major health burden affecting 537 million adults worldwide, characterized by chronic metabolic disorder and various complications. This case control study aimed to assess the impact of type 2 diabetes mellitus (T2DM), including hyperglycemia levels, on hematological parameters and complete blood count (CBC) derived parameters.
Methods
UNASSIGNED
A total of 250 known diabetic patients from the Jazan Diabetic Center, Saudi Arabia, between January 2021 and December 2022, along with 175 healthy adult controls were recruited from Jazan Hospital's blood donation center. Demographic characteristics, medical histories, and relevant factors such as gender, age, BMI, treatment, disease duration, and comorbidities were collected with informed consent.
Results
UNASSIGNED
The results of the red blood cell (RBC) count, RBC indices, and mean platelet volume showed significant differences between patients and controls, while the white cell (WBC) and platelet count were comparable between the two groups. CBC-derived parameters, especially neutrophil/lymphocyte ratio (NLR), and platelet/neutrophil ratio (PNR) exhibited significant differences.
Conclusion
UNASSIGNED
CBC and derived parameters serve as inexpensive tools for T2DM patients monitoring, indicating early blood cell alterations and potential development of anemia. Further studies are needed to explore their role in predicting T2DM pathogenesis and progression, aiming to reduce severe complications, mortality and morbidity.
Identifiants
pubmed: 37822802
doi: 10.2147/DMSO.S422373
pii: 422373
pmc: PMC10563775
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3123-3132Informations de copyright
© 2023 Essawi et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest in this work.
Références
Hematology. 2011 Mar;16(2):86-9
pubmed: 21418738
J Diabetes Complications. 2009 Mar-Apr;23(2):89-94
pubmed: 18358749
Pak J Med Sci. 2019 Nov-Dec;35(6):1611-1615
pubmed: 31777502
Sci Rep. 2019 Nov 7;9(1):16208
pubmed: 31700048
Infect Drug Resist. 2022 Apr 29;15:2359-2368
pubmed: 35517897
Cardiovasc Diabetol. 2008 Aug 27;7:25
pubmed: 18752687
Diabetes Metab Syndr Obes. 2016 Mar 17;9:91-9
pubmed: 27042134
Platelets. 2004 Dec;15(8):475-8
pubmed: 15763888
J Diabetes Res. 2020 Apr 28;2020:6219545
pubmed: 32405503
Diabetes Care. 2013 Feb;36(2):276-82
pubmed: 22961572
Bratisl Lek Listy. 2021;122(7):474-488
pubmed: 34161115
Nat Clin Pract Nephrol. 2007 Jan;3(1):20-30
pubmed: 17183259
Diabetes. 2003 Jul;52(7):1799-805
pubmed: 12829649
J Am Soc Nephrol. 2005 Nov;16(11):3403-10
pubmed: 16162813
Electron Physician. 2017 Sep 25;9(9):5206-5211
pubmed: 29038698
J Intern Med. 1998 Dec;244(6):437-41
pubmed: 9893096
Kidney Int. 2003 Apr;63(4):1499-507
pubmed: 12631367
J Blood Med. 2021 Jan 27;12:33-42
pubmed: 33536804
Vasc Health Risk Manag. 2013;9:237-43
pubmed: 23690689
PLoS One. 2022 Jul 27;17(7):e0272145
pubmed: 35895700
Int J Gen Med. 2020 Oct 05;13:765-770
pubmed: 33116767
J Clin Lab Anal. 2021 Jan;35(1):e23607
pubmed: 33128497
J Clin Pathol. 2006 Feb;59(2):146-9
pubmed: 16443728
Diabetes Metab Res Rev. 2013 Mar;29(3):220-6
pubmed: 23280928
J Int Med Res. 2014 Apr;42(2):581-8
pubmed: 24567354
Diabetes Care. 2009 Apr;32(4):525-7
pubmed: 19336636
Int J Mol Sci. 2019 Dec 16;20(24):
pubmed: 31888259
Diabetes Metab Syndr Obes. 2015 Oct 30;8:525-33
pubmed: 26586957
J Diabetes Sci Technol. 2008 Nov;2(6):1130-8
pubmed: 19885302
J Lab Physicians. 2012 Jan;4(1):5-9
pubmed: 22923915
Infect Drug Resist. 2021 Nov 23;14:4859-4864
pubmed: 34848978
J Diabetes Complications. 2004 May-Jun;18(3):173-6
pubmed: 15145330
PLoS One. 2021 Jun 14;16(6):e0253286
pubmed: 34125859
Saudi Med J. 2021 Apr;42(4):370-376
pubmed: 33795491
JAMA. 2001 Jul 18;286(3):327-34
pubmed: 11466099
Afr Health Sci. 2019 Mar;19(1):1602-1606
pubmed: 31148989